About

An independent resource for comparing ibogaine and DMT research.

Prismwell helps people understand differences in evidence, effects, risks, and research pathways for ibogaine and N,N‑DMT.

Prismwell exists to bring clear, evidence‑first context to complex questions about psychoactive research. Our editorial focus is independent: we synthesize study data, regulatory summaries, and public registries so readers can see the limits of current knowledge without being steered toward a specific treatment or product.

We are not a clinic or medical provider — our materials do not replace professional advice.

Close-up detail photograph used to illustrate editorial perspective on ibogaine and DMT comparisons

Our editorial approach

We compile and summarize primary studies, clinical trial registries, and authoritative guidance so readers can compare evidence side‑by‑side. When a claim hinges on trial design, sample size, or regulatory status we point to the underlying registry or paper rather than paraphrasing it into certainty. For a sense of how trial registries inform conclusions, we sometimes link directly to registration portals or literature syntheses as part of our analysis; for example, we reference public trial listings and guidelines when describing research pathways.

Our approach emphasizes transparency: sources, date stamps, and uncertainty are always surfaced.

What we cover

Prismwell organizes content into comparative modules, mechanism summaries, safety briefings, and an evidence snapshot. Each module is written to stand alone so a reader can review risks, trial status, and research gaps without needing specialist background.

How we source and vet information

Our editorial team reviews peer‑reviewed journals, clinical trial registries, and governmental guidance. For methodological claims we refer to established references such as the National Library of Medicine's ClinicalTrials.gov registry and broadly accepted summaries on trial design from universities and public health agencies when applicable.

Where appropriate, we also cite concise reference material—this helps set context; for instance, overviews on evidence synthesis frameworks are commonly drawn from recognized university resources.

Editorial principles

Our decisions are guided by a few clear, repeatable commitments. These principles shape which studies we highlight and how we phrase uncertainty.

Evidence before claims — prioritize primary data and transparent methods.
Safety context — always present potential risks alongside potential benefits.
Plain language — write for a curious adult reader without specialist jargon.
Uncertainty acknowledged — avoid definitive claims when the evidence is limited.

To learn about services that support deeper dives into methods or sourcing, see our description of offerings on the services overview.

Example external references we use to ground methodological points include broad public resources such as the trial registry maintained by the U.S. National Library of Medicine (clinicaltrials.gov) and university guidance on evidence appraisal (for methods, see a sampling at Harvard University).

Transparency & sourcing

When we reference clinical activity or policy we prefer primary sources. For instance, when discussing treatment landscapes we cite registries and program listings; in one editorial piece we linked to an external resource covering clinical use and historical practice at ibogaine and methadone program overview as part of contextual reporting.

How we display source confidence

Each piece includes a short "confidence" note describing whether conclusions rest on randomized trials, observational reports, or preclinical studies. This helps readers weigh the strength of claims without inferring clinical endorsement.

Landscape photograph used to illustrate transparent sourcing and editorial context

Frequently asked questions

Is Prismwell a treatment provider?

No. Prismwell is an independent information resource, not a clinic, licensed treatment center, or medical provider. Our materials are educational and do not substitute for professional medical advice.

For official clinical guidance consult regulatory or professional bodies such as the U.S. Food and Drug Administration (fda.gov) and national health services.

How can I trust the sources you use?

We prioritize peer‑reviewed papers, registered clinical trials, and official guidance. Where interpretation is necessary, we explain our reasoning and link to the underlying material so readers can judge for themselves. For methodological foundations we reference established literature appraisal frameworks like those summarized by universities and public health agencies.

Can I request that my organization be listed or corrected?

We welcome corrections to factual items. Use the Contact page to send verifiable source material; we will review and update content when warranted.

Independent by design

We remain publisher-first: the site's role is to clarify evidence and safety context rather than to promote interventions. If you're exploring the landscape, start with our overview modules and consult licensed professionals before making decisions.

Explore services